Assessment of clinical risk factors of osteoporosis, bone mineral density and fracture prevalence in systemic sclerosis
Rose‐Marie Javier(Laboratoire National de Référence), Jean Sibilia(Immunologie, Immunopathologie et Chimie Thérapeutique), Arnaud Theulin(Hôpitaux Universitaires de Strasbourg), J.-E. Gottenberg(Université de Strasbourg), Emmanuel Chatelus(Laboratoire National de Référence)
Cited by 0
Related Papers
<i>MUC5B</i> Promoter Variant and Rheumatoid Arthritis with Interstitial Lung Disease
|New England Journal of Medicine|2018|501
Incidence and Prevalence of Systemic Sclerosis: A Systematic Literature Review
|Seminars in Arthritis and Rheumatism|2007|456
Effects and safety of rituximab in systemic sclerosis: an analysis from the European Scleroderma Trial and Research (EUSTAR) group
|Annals of the Rheumatic Diseases|2014|432
Hydroxychloroquine in systemic lupus erythematosus: results of a French multicentre controlled trial (PLUS Study)
|Annals of the Rheumatic Diseases|2012|207